Genetic Analysis Of Alzheimer s Disease

$897,076ZIAFY2018AGNIH

National Institute On Aging

Investigators

Linked publications, trials & patents

Paper 31417202 Paper 30706571 Paper 30102995 Paper 29544907 Paper 29379882 Paper 29329552 Paper 29181857 Paper 29103623 Paper 27939698 Paper 27776828 Paper 27524508 Paper 27289440 Paper 27249223 Paper 26803359 Paper 26643944 Paper 25687773 Paper 25607358 Paper 25104557 Paper 24973356 Paper 24880964 Paper 24794858 Paper 24439484 Paper 24336208 Paper 23921447 Paper 23428180 Paper 23360175 Paper 23318515 Paper 22795969 Paper 22723018 Paper 22503161 Paper 22349451 Paper 22216764 Paper 22153900 Paper 22027014 Paper 21887711 Paper 21654062 Paper 21460840 Paper 21085570 Paper 20534741 Paper 20460622 Paper 20209083 Paper 20020531 Paper 19734902 Paper 19571725 Paper 19271249 Paper 18667258 Paper 18661559 Paper 18387709 Paper 16914853 Paper 16472206 Paper 16042549 Paper 16042548 Paper 15740841 Paper 15668448 Paper 15464261 Paper 15165693 Paper 14976159 Paper 14746507 Paper 14688411 Paper 12846985 Paper 12810495 Paper 12794314 Paper 12714109 Paper 12566161 Paper 12231449 Paper 12177383 Paper 12141310 Paper 12130773 Paper 12034808 Paper 11983299 Paper 11920850 Paper 11911995 Paper 11897170 Paper 11895378 Paper 11706935 Paper 11684347 Paper 11680797 Paper 11425935 Paper 11406330 Paper 11379823 Paper 11140686 Paper 11079548 Paper 11056541 Paper 11027672 Paper 11018310 Paper 11001930 Paper 10720282

Abstract

We continue to be a contributor to the reanalysis of large tracts of genome wide association data and much of this work, which identifies several new loci, and a converging molecular pathway, has been published. Most recently we continue our efforts using second generation sequencing (which previously lead to the identification of TREM2 and TREML2, and PLD3 variants as a risk factor for Alzheimer's disease). We have followed up on that work with continued characterization of known AD loci in relatively small series of patients. We are contributing members to consortia that continue to investigate various aspects of AD genetics. We are analyzing longitudinal high dimension data from AD patients using a series of machine learning and artificial intelligence methods

View original record on NIH RePORTER →